Apps

openserveblockversewordysbillionaire.aiyourlistWhiteboardAppquizieunschool

News

Home
Politics
World
Sports
Markets
Business
Entertainment
Music
Health
Tech
Science
Good News

Want your own hosted, self-optimizing clone of this — or any OpenServe site? Open Development for enterprise →

© OpenServe Holdings LLC

Privacy Notice Data rights Terms of Service Feedback Cookie NoticeHelp Acceptable Use Copyright AI Notice Your Privacy Choices Subprocessors Data Processing Addendum Installed App Terms Company Solutions Free assessment Investors Get the app Contact

IJR News — today's news from every side

📊 Approval moversDonald Trump100%

Novo says Wegovy trial moved 40% of young children out of obesity — 6hIn Novo Nordisk's STEP Young phase 3 trial, once-weekly semaglutide plus lifestyle changes reduced BMI and 40.4% of children aged 6-11 with obesity no longer met obesity criteria after 68 weeks, versus 0% on placebo. Safety remained consistent with prior semaglutide studies, adding to the growing body of pediatric obesity treatment data.

Chris Dalton Glad there's finally something beyond diet and exercise lectures for kids who genuinely struggle, this could change a lot of families' lives.

Novo Nordisk launches Wegovy pill in Germany as Eli Lilly readies rival — 6dNovo Nordisk is rolling out Wegovy as an oral weight‑loss pill in Germany, the EU’s first market to receive the formulation after EU approval, with prices expected around €170–€280 and strong competition from Eli Lilly’s Foundayo on the horizon. The launch leverages Wegovy’s dominant position in the oral obesity market, while analysts weigh the impact of the tablet on growth, pricing, and payer access across Europe.

Tom Gallagher Curious how many insurers in Germany will actually cover this at launch, oral obesity meds still feel like they're priced for a niche market.

China's Novo Nordisk Oral Wegovy Filing AcceptedBusiness — Aug 27, 2026Novo Nordisk trades near its average price target as China regulators accept the oral Wegovy application, underscoring a regulatory catalyst amid strong GLP-1 growth potential. The China market is heating up with Eli Lilly and others racing to offer pill-based options, and analysts project GLP-1 sales in China to surge to around 30 billion yuan in the next five to seven years, driving competition and market leadership shifts.

Video — YouTubeMISTRIAL: MA v. Lindsay Clancy - Day 28 | Accused Killer Mom TrialCOURT TV · 3.4M views · Sep 4, 2026

Novo Nordisk Tests Lower Wegovy Doses — Aug 19, 2026Novo Nordisk is conducting a late-stage study to identify the lowest effective dose of Wegovy, testing two low doses against placebo in 450 participants as it seeks to preserve its share in a obesity drug market projected to exceed $100 billion annually by 2030. The trial, which began on August 12 and runs through 2028, follows competitive pressure from Eli Lilly and comes after Wegovy's recent sales performance, with dose strengths undisclosed.

IJRTrump Admin Splinters Over AI’s Right To Train On Americans’ Copyrighted WorkDylan Kresak · 4 min · 3h

Biden-Harris Admin Moves To Shell Out Tens Of Billions In Taxpayer Dollars For Weight-Loss DrugsReporting — Nov 26, 2024The Biden-Harris administration proposed a new rule Tuesday to cover the cost of weight-loss drugs like Ozempic, Wegovy and Mounjaro for millions of Americans. The Department of Health and Human Services (HHS)…

RankingMost underrated cities in AmericaAmerica's biggest cities hog all the spotlight, while dozens of smaller gems get overlooked despite great food, culture, and character. These underrated cities deserve recognition beyond the usual coastal favorites. Cast your vote and help crown the most underappreciated city in the country.693 votes · 21 candidates